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Background: A number of studies have reported on the effects of iron supplementation in low birth weight
infants; however, no systematic review of the available evidence has been conducted to date. Hence, we
performed a systematic review of the literature to examine the effects of iron supplementation on hematologic iron
status, growth, neurodevelopment, and adverse effects in low birth weight/premature infants.
Methods: We searched the Cochrane Library, Medline, and PubMed for articles reporting on the effects of iron
supplementation in low weight infants. The following search terms were used: “preterm born infant(s)/children”;
“preterm infants”; “prematurely born children” “weight less than 1500 g at birth”; “born prematurely”; “low birth
weight infant(s)”; “infants born preterm”; “prematurity”; “small-for-gestational age”; “very small gestational age
infants”; “iron supplementation”; “iron intake”; “iron supplements”; “ferric and/or ferrous compounds”; and “ferrous
sulphate/fumarate/sulfate”.
Results: A total of 15 studies were identified and included in the systematic review. Supplemental iron was given
orally or as an iron-fortified formula in 14/15 studies. The duration of treatment ranged from 1 week to 18 months.
Iron supplementation significantly increased hematologic measures of iron status (including hemoglobin,
hematocrit, serum ferritin) relative to placebo or over time in most studies. All controlled studies that examined
iron-deficiency anemia (IDA)/ID reported a decreased prevalence of IDA/ID with iron supplementation. Dose
dependent decreases in the prevalence of IDA/ID were reported in several studies. Of the 5 studies reporting on
growth, none found any significant effect on growth-related parameters (length, height, weight, and head
circumference). Only 2 studies reported on neurodevelopment; no marked effects were reported. There were no
consistently reported adverse effects, including oxidative stress, inhibited nutrient absorption, morbidity, or the
requirement for blood transfusion.
Conclusion: The available data suggest that iron supplementation increases the levels of hematologic indicators of
iron status and reduces the prevalence of IDA/ID in low birth weight/premature infants. There is insufficient
evidence to make a definitive statement regarding the effects of iron supplementation on growth,
neurodevelopment, or the occurrence of adverse effects in low birth weight/premature infants.
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Iron is an essential micronutrient that plays a critical
role in many cellular functions and processes, including
growth and development. As such, having an adequate
supply of iron, along with other micronutrients, is
thought to be particularly important for infants [1]. Low
birth weight infants, including premature infants, are* Correspondence: YIYijingmei1201@126.com
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reproduction in any medium, provided the orespecially susceptible to developing iron deficiency anemia
(IDA) because these infants have smaller iron stores at birth
and a greater iron requirement concurrent with a rapid in-
crease in the red cell mass than term infants [2-5].
Increased hemolysis, shortened red blood cell lifespan, low
circulating erythropoietin levels, blood sampling, and blood
loss associated with medical and surgical procedures may
all contribute to anemia in low birth weight and premature
infants.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clude impaired development [6-11] and altered longer term
neurodevelopment [12-14]. Due to the high risk of IDA,
iron supplementation is recommended for low birth weight
infants [15]. Whether or not such supplementation is of
any benefit to low birth weight infants is unclear. Interes-
tingly, the findings from several systematic reviews / meta-
analyses examining the effects of iron supplementation
in children suggest that supplementation improves
hematologic markers of iron status [16,17], but does not
markedly improve growth, or mental or motor develop-
ment [18-20]. Although a number of studies have reported
on the effects of iron supplementation in low birth weight
infants, no systematic review of the available evidence has
been conducted to date. Hence, we performed a systematic
review of the literature, focusing on the effects of iron sup-
plementation in low birth weight / premature infants on
hematologic iron status, growth, and neurodevelopment.
We also examined potential adverse effects of iron
supplementation.Methods
Search Strategy
The Cochrane Library, Medline, and PubMed databases
were searched from inception to June 2011. We limited
the searches to include only articles written in English
using the following terms: “preterm born infant(s) /
children”; “preterm infants”; “prematurely born children”
“weight less than 1500 g at birth”; “born prematurely”;
“low birth weight infant(s)”; “infants born preterm”; “pre-
maturity”; “small-for-gestational age”; “very small gesta-
tional age infants”; “iron supplementation”; “iron intake”;
“iron supplements”; “ferric and/or ferrous compounds”;
and “ferrous sulphate / fumarate / sulfate”. Boolean opera-
tors (not, and, or) were also used in succession to narrow
and widen the search. To locate unpublished materials
and avoid systemic bias, we manually searched the refe-
rences lists of original and review articles for symposia
proceedings, poster presentations, and abstract from
major pediatric association meetings.Eligibility Criteria
Studies were eligible for inclusion if they involved infants
who were of low birth weight (< 2500 g) or premature
(gestational age< 35 weeks) and received iron supple-
mentation through the enteral (formula or iron drops)
or parenteral routes. Studies involving supplementation
of other micronutrients were also eligible for inclusion if
the only difference between the treatment and the con-
trol groups was iron supplementation.
Studies were excluded if there was no definite length
of treatment available, or if supplementation was com-
bined erythropoietin treatment.The search and inclusion and exclusion criteria were
developed by an investigative team, including experts in
the field of pediatric development and nutrient research.
Our team included a biostatistician who was instrumen-
tal in defining the criteria.
Study Selection
The first step in study selection was the exclusion of
duplicates (ie, reports of the same study). The title and
abstract of the trials retrieved in the search were
scanned and studies that were obviously irrelevant were
excluded. The full text of each remaining study was
reviewed to establish eligibility and all relevant informa-
tion and data were extracted.
Data Extraction and Quality Assessment
Data were extracted by 3 independent reviewers. Each
reviewer used a standardized data collection form to in-
crease uniformity and reduce bias. In the case of dis-
crepancy, the reviewers made a consensus decision. The
following information / data were extracted from each
eligible study: first author; year of publication; journal;
eligibility criteria; definition of premature or low-birth
weight; number of cases and control; population demo-
graphics; hematological data (hemoglobin, hematocrit,
serum iron) before iron supplementation; iron supple-
ment dose; duration of iron supplementation; hema-
tological data after iron supplementation; growth status
after iron supplementation; and adverse effects of iron
supplementation.
The quality of each study identified for inclusion was
assessed using the Delphi list for quality assessment of
randomized clinical trials [21].
Results
Literature Search
A total of 2065 articles were identified by searching the 3
databases and a further 3 articles were identified by biblio-
graphic searches (Figure 1). Of these articles, 3 duplicates
were subsequently excluded. Abstracts and titles for the
remaining 2065 articles were reviewed and 1962 were sub-
sequently excluded, typically because outcomes of interest
were not presented or maternal supplements were given.
Full text review led to exclusion of a further 88 articles.
Hence, a total of 15 articles [2,22-35] were included in the
systematic review.
Study Characteristics
The studies included in this systematic review were pub-
lished between 1960 and 2010 and included low birth
weight infants aged from birth to 80 days (Table 1).
The number of low birth weight infants in the iron
supplementation treatment group ranged from 16 to 90,
with most studies having 20 to 40 infants per iron
Figure 1 Study flow diagram.
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monly given orally [2,23,27,29-35] or as an iron-fortified
formula [2,24-26,28]. In 1 study, iron was given by intra-
muscular injection [22]. The duration of iron supple-
mentation varied considerably, ranging from 1 week up
to 18 months.
The quality of studies included in the systematic re-
view was generally acceptable for most items of quality
assessment. The majority of studies employed a method
of randomization (10/15; 66.7%), had similar between
group characteristics at baseline (9/15; 60%), specified
eligibility criteria (13/15; 86.7%), provided point esti-
mates and measures of variability for the primary
outcome measures (13/15; 86.7%), and included an
intention-to-treat analysis (12/15; 80.0%). Only 6/15
(40%) studies provided any definitive information about
blinding (outcome assessor, care provider, or patient)
(Table 2).
Meta-analyses of the extracted data were not per-
formed because mean values were not available or doses
were not adjusted by body weight in the majority of the
studies identified. There was significant heterogeneity
(data not shown) among the 3 studies in which mean
values were available and dose was adjusted for body
weight [31,34,35].Effect of Iron Supplementation on Hematologic
Parameters
All but 1 study reported on the effects of iron supplementa-
tion on hematologic measures of iron status (Table 3). The
majority of studies reported that iron supplementation sig-
nificantly increased hematologic measures of iron status
relative to control. Specifically, Hammond et al. reported
that premature infants treated for 2–4 days with intra-
muscular iron-dextran (100 mg) had significantly higher
hemoglobin concentrations and hematocrit values from
3 months of age onwards and significantly higher erythro-
cyte counts from 5 months of age onwards compared with
premature infants in the control group [22]. In another
study, Lundstrom et al. found that low birth weight infants
treated for approximately 6 months with an oral iron
supplement (2 mg/kg/day) had significantly higher
hemoglobin, serum ferritin, mean corpuscular volume
(MCV), and transferrin saturation levels at 3 months com-
pared with low birth weight infants in the control group
[2]. Iwai et al. similarly reported that low birth weight
infants fed an iron-fortified formula (8 mg/L) for 6 months
had significantly higher hemoglobin, serum ferritin, and
MCV concentrations than control infants fed human milk
only [24]. Aggarwal et al. also reported that low birth
weight infants fed oral iron in a drop formulation (3 mg/
Table 1 Characteristics of the studies examining the effects of iron supplementation in low birth weight infants
Study Agea Sample
Sizeb





2-3 wks T: 26
C: 22
Premature birth T: 100 mg intramuscular iron-dextran;
C: No ironTreatment: 1 mo; Follow-up:
12 mo
Hematologic: Hb, HCT, PCV, RBC
Brozovic et al.
1974[23]
5 wks 47 GA: 29–37 wks
BW: 920–1870 g
36.3 mg/d oral ironTreatment and
follow-up: 9 mo
Hematologic: Hb, SI, TIBC
Lundstrom et al.
1977[2]
2 wks T: 40
C: 50
BW: 1050–2000 g T: 2 mg/kg/d oral iron; C: No
ironTreatment and follow-up: 6 mo
Hematologic: Hb, MCV, reticulocyte
count, SI, SF, TRNSAT, TIBC
Iwai et al.
1986[24]





Formula: 8 mg/L oral ironTreatment:
3 mo; Follow-up: 6 mo








GA: < 35 wks
BW: < 1800 g
High: 1.3 mg/kg/d oral iron; Low:
0.3 mg/kg/d oral iron; Milk: 0.3 mg/kg/d
ironTreatment: 25–34 d; Follow-up: ~11-13
wks
Hematologic: Hb, MCV, TRNSAT, SF,




3 d A: 29
B: 34
C: 15
GA: ≥ 32 wks
BW: < 1750 g
A: 0.9 mg/dL iron formula (1.17 mg/kg/d);
B: 0.5 mg/dL iron formula (0.81 mg/kg/d);
C: 0.9 mg/dL iron formula until term and
then 0.5 mg/dL iron formula (0.86 mg/kg/d)
Treatment: 6 mo; Follow-up: 12 mo
Hematologic: Hb, plasma ferritin
Franz et al.
2000[27]
14/61 d T: 68
C: 65
BW: < 1301 g T: 2–4 mg/kg/d oral iron once enteral
feeding was tolerated; C: No ironTreatment
and follow-up: Until 61 days of age






BW: < 2500 g High: 20.7 mg/L iron formula (0.6-5.9 mg/
kg/d); Normal: 13.4 mg/L iron formula (0.6-
3.0 mg/kg/d)Treatment and follow-up:
12 mo
Hematologic: Hb, HCT, SF, TRN,
TRNSAT, MCV, PLFE
Development: WTZ, GDA, HTZ
Oxidative stress: MDA, PLZN, PLCU,
FRAG, CAT, SOD, GHSPx




50-80 d T: 37
C: 36
GA: ≥ 37 wks
BW: < 2500 g
T: 3 mg/kg/d oral iron; C: No ironTreatment
and follow-up: 8 wks
Hematologic: Hb, SF, microcytic
hypochromic, NCHC, NCNC




7-60 d T: 16
C: 16
GA: 24–32 wks T: 3–12 mg/kg/d oral iron;
C: No ironTreatment and follow-up:
2–3 wks
Hematologic: RBC, SI, SF, TIBC, ZnPP/








GA: < 32 wks 5 mg/kg/d oral ironTreatment and
follow-up: 4–6 wks





14/61 d Early: 90
Late: 74
BW: < 1301 g Early (14 d): 2–4 mg/kg/d oral iron;
Late (61 d): 2 mg/kg/d oral ironTreatment:
until BW= 1.6x birth BW;






Assessment Battery for Children,
visual impairment, and
Child Behavior Check List)
Braekke et al.
2007[33]
5 wks 21 GA: < 32 wksBW:
< 1500 g
9.4 mg/kg/d oral ironTreatment and
follow-up: 1 wk
Hematologic: Hb, reticulocytes, iron,
SF, TRNSAT
Oxidative stress: urine isoprostane,
urine 2,3 dinor, plasma total
hydroperoxides
Plasma antioxidants: AA, TAA, DHAA,




2 wks T: 22,
C: 24
BW: < 1500 g T: 3–4 mg/kg/d oral iron;
C: No ironTreatment and follow-up:
60 d
Hematologic: SF, HbAdverse effects:
morbidity
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6 wks T1: 78
T2: 82
C: 83
BW: 2000–2500 g T1: 1 mg/kg/d oral iron;
T2: 2 mg/kg/d oral iron;
C: No ironTreatment: 6 wks to 6 mo of age;
Follow-up: up to 6 mo
Hematologic: Hb, SF, MCV, PLFE, TRN,
TRNSAT, sTfR, ID, IDA
Development: weight, weight SD






AA, ascorbic acid; BW, birth weight; C, control; CAT, catalase; CGA, corrected gestational age; d, days; DHAA, dehydroascorbic acid; FRAG, red blood cell fragility;
GA, gestational age; GDA, Griffiths’ Development Assessment; GHSPx, glutathione peroxidase; GGT, Gamma-glutamyl transferase; Hb, Hemoglobin; HCT,
hematocrit; HTZ, height for age z score; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; ID, iron deficiency; IDA, iron
deficiency anemia; MCV, mean corpuscular volume; MDA, malondialdehyde; mo, month; NA, not available; NCHC, normocytic hypochromic; NCNC, normocytic
normochromic; PCV, packed cell volume; PLFE, plasma iron; PLCU, plasma copper; PLZN, plasma zinc; RBC, red blood cell; ROP, retinopathy of prematurity; SF,
serum ferritin; SI, serum iron; SOD, superoxide dismutase; sTfR, soluble transferrin receptor; T, iron supplementation group; TAA, total ascorbic acid; TIBC, total iron
binding capacity; TRN, transferrin; TRNSAT, transferrin saturation; wks, weeks; WTZ, weight for age z score; ZnPP/H, zinc protoporphyrin to heme ratio.
a Age at the start of supplementation.
b Data analysis sample size.
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(for age, hemoglobin, ferritin, and maternal hemoglobin)
hemoglobin concentrations from 4 weeks onwards com-
pared with control infants [29]. Finally, Berglund et al.
found that marginally low birth weight infants fed an oral
iron supplement (1 or 2 mg/kg/day) between 6 weeks and
6 months of age had significantly higher hemoglobin, MCV,
ferritin, transferrin, iron, transferrin saturation, and trans-
ferrin receptor levels compared with control infants [35].
In a non-placebo controlled study, Arnon et al. found
that premature infants fed enteral iron (5 mg/kg/day)
from 2 weeks of age to 8 weeks of age had significantly
higher hemoglobin, reticulocyte, iron, and ferritin con-
centrations compared with premature infants fed enteral
iron (5 mg/kg/day) from 4 weeks of age to 8 weeks of
age [31]. In another non-placebo controlled study,
Braekke et al. reported that very low birth weight infants
given oral iron supplementation (9.4 mg/kg/day) from
6 weeks of age had significantly higher iron and transfer-
rin saturation levels at 7 weeks of age [33].
A small number of studies included in the systematic
review found that iron supplementation had no signifi-
cant effect on hematologic measures of iron status rela-
tive to control. These include studies by: Friel et al., in
which low birth weight infants were fed either a normal
(0.6-3.0 mg/kg/day) or high (0.6-5.9 mg/kg/day) iron for-
mula from birth for 12 months [28]; Miller et al., in
which 7 to 60 day-old premature infants were given oral
iron (3 to 12 mg/kg/day) or control (no iron) for 3 weeks
[30]; Sankar et al., in which very low birth weight infants
were fed oral iron (3 to 4 mg/kg/day) or control (no
iron) from 2 weeks of age until 60 days of age [34].
A study by Griffin et al. compared the effects of for-
mulations containing either 0.9 mg/dL iron or 0.5 mg/
dL iron in premature infants and found that there were
no dose-dependent differences in hematological indica-
tors of iron status [26]. In another study, Franz et al.reported that early iron supplementation (2 to 4 mg/kg/
day once enteral feeding was tolerated) had no signifi-
cant impact on indicators of iron status in infants with a
birth weight <1301 g [27].
Effect of Iron Supplementation on the Prevalence of Iron
Deficiency and Iron-Deficiency Anemia
Most studies reported on the prevalence of iron deficiency
(ID) and/or IDA (Table 3). All controlled studies that exam-
ined the prevalence of ID and/or IDA found that the preva-
lence of ID and/or IDA was lower in infants who received
iron supplementation compared with infants who did not
receive iron supplementation [2,22,24,25,35]. Several stud-
ies also reported dose-dependent effects of iron supplemen-
tation on the prevalence of ID and/or IDA, with higher
iron doses being associated with decreased prevalence
[25,26,35]. In contrast, Friel et al. found no obvious effect
of dose, with 4/29 (13.8%) infants in the high iron supple-
mentation group and 2/29 (6.9%) infants in the normal iron
supplementation group having ID after 12 months of treat-
ment [28]. Franz et al. also found that iron supplementation
was associated with a decreased prevalence of ID [27].
Only 1 study found no obvious benefit of iron supple-
mentation on the prevalence of ID and/or IDA. Brozovic
et al. reported that oral iron (36.3 mg/day) from 5 weeks to
9 months of age did not prevent ID in premature low birth
weight infants [23].
Effect of Iron Supplementation on Growth and
Neurodevelopment
Five studies included in the systematic review examined
the effect of iron supplementation on growth, whereas
only 2 studies examined the effect of iron supplementa-
tion on neurodevelopment (Table 4). None of the studies
that examined growth-related variables, including
growth rate, length, height, head circumference, and
weight, found any effect of iron supplementation
Table 2 Quality assessment of studies examining the effects of iron supplementation in low birth weight infants
Item Was a method of
randomization
used?




















and measures of variability








Y Y NA NA NA NA Y Y
Brozovic et al.
1974[23]
NA NA Y NA NA NA Y N
Lundstrom et al.
1977[2]
N NA Y NA NA NA Y Y
Iwai et al. 1986[24] NA NA N NA N N Y Y
Hall et al. 1993[25] Y Y Y NA NA Y Y Y
Griffin et al.
1999[26]
Y N Y NA NA Y N Y
Franz et al.
2000[27]
Y Y Y NA NA NA Y N
Friel et al.
2001[28]
Y Y Y NA NA NA Y Y
Aggarwal et al.
2005[29]
Y Y Y NA NA Y Y Y
Miller et al.
2006[30]
N N Y NA NA NA N Y
Arnon et al.
2007[31]
Y Y Y NA NA NA Y N
Steinmacher et al.
2007[32]
Y Y Y NA NA NA Y Y
Braekke et al.
2007[33]
N NA Y NA NA NA Y Y
Sankar et al.
2009[34]
Y Y Y Y N Y Y Y
Berglund et al.
2010[35]
Y Y Y NA Y Y Y Y

















Table 3 Effects of iron supplementation on hematologic parameters in low birth weight infants







higher in T group by 3
mo; erythrocyte count
significantly higher in T




27.3 vs 7.7 %
IDA (C vs T)
Early iron suppl. accelerates
recovery from early IDA
27 % loss to follow up; other
vitamins were administrated; BW
and hematologic measurements
slightly higher in C vs T group
Brozovic et al
1974[23]
At 3 mo of age, most




NA > 50 % IDA Iron suppl. was insufficient to
prevent IDA in most infants
No control group; all infants





SF, Hb, MCV, TRNSAT
significantly higher in T
group by 3 mo
Reticulocyte
count
67 vs 0 % ID
(C vs T)
LBW infants who do not receive
iron suppl. may develop ID by 3
mo of age; 2 mg/kg/d iron is
adequate for the prevention of
IDA
23 % loss to follow up; after 3
mo of age, an increasing number
of C group infants were
excluded; SF was higher than
normal in C group; iron suppl.
given in 2 different forms
Iwai et al.
1986[24]
Hb, SF, MCV significantly
higher in the formula
group by 4 mo
RBC, SI, TIBC 86 vs 33 % ID
(human milk
vs formula)
Breast-fed infants have a high
risk of ID
Infants in formula group had
slightly higher BW than those in
human milk group; iron status of




ferritin lowest in low iron
groupDischarge: plasma
ferritin significantly lower
in both formula groups 8
wks after discharge; MCV,





27, 69, 76 %
IDA (high, low,
human milk)
Preterm infants receive more
benefit from receiving preterm
infant formula containing
1.3 mg/kg/d iron vs 0.3 mg/kg/d
44 and 25 % of infants in high
and low dose groups dropped
out because of prematurity
related diseases; 13 % of infants




NA Hb 18 vs 27 % ID
(A vs B)
0.81-1.17 mg/kg/d iron seems to
meet the iron nutritional needs
of preterm infants
In group C, BW was slightly
lower, fewer transfusions were
received, and Hb was
significantly lower vs A and B; no
ferritin data for Group C
Franz et al.
2000[27]
NA All markers of iron
nutrition
14.7 vs 40.0 %
ID (T vs C)
Fewer infants in group T
received blood transfusion vs
group C; early iron suppl. is
feasible and safe in LBW infants
34 % loss to follow up; group C




NA No difference in
any hematologic
parameters
6.9 vs 13.8 %
ID (normal vs
high)
In terms of cognitive outcome,





Adjusted Hb higher in T
group
SF NA Iron suppl. marginally increases
Hb in LBW infants
42 % loss to follow up
Miller et al.
2006[30]
NA SI, SF, TIBC, sTfR NA Corrected reticulocyte count
higher in the T group suggesting
improved erythropoiesis
Iron suppl. was adjusted by
individual iron status; CGA,






higher in the 2 wk
group at 8 wks
Reticulocytes, iron,
ferritin at 4 wks of
age
NA Iron suppl. to preterm infants as
early as 2 weeks of age was
more beneficial for iron status,
than at 4 weeks of age
All infants given 25 mg/d oral





Ferritin NA Oral iron did not change markers
of oxidative stress in LBW infants
No control group; all infants
received other vitamins,
including vitamin E; 15 % loss to




NA SF, HCT, Hb NA Iron suppl. at 2 weeks of age did
not improve hematological
parameters at 2 mo of age in
preterm very LBW infants
Iron suppl. group received folic
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Table 3 Effects of iron supplementation on hematologic parameters in low birth weight infants (Continued)
Berglund et al.
2010[35]





2.7, 0, 9.9 %
IDA (T1, T2, C)
9.5, 3.8, 35.8 %
ID (T1, T2, C)
Marginally LBW infants had
higher risk of ID and IDA,
especially those exclusively
breastfed; 2 mg/kg/d oral iron
significantly improved iron status
and reduced IDA risk
BW, birth weight; C, control; CGA, corrected gestational age; Hb, Hemoglobin; HCT, hematocrit; ID, iron deficiency; IDA, iron deficiency anemia; LBW, low birth
weight; MCV, mean corpuscular volume; mo, month; ROP, retinopathy of prematurity; RBC, red blood cell; SF, serum ferritin; SI, serum iron; sTfR, soluble transferrin
receptor; suppl., supplementation; T, iron supplementation group; TIBC, total iron binding capacity; TRN, transferrin; TRNSAT, transferrin saturation; wks, weeks; NA,
not available.
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Friel et al. found that iron supplementation did not im-
prove cognitive development as measured using Grif-
fiths’ Development Assessment [28]. In the other study,
which focused on examining the effects of iron supple-
mentation on neurocognitive development in premature
infants weighing< 1301 g, Steinmacher et al. found that
early supplementation (< 61 days of age) tended to im-
prove neurocognitive and psychomotor development
compared with late supplementation (≥ 61 days of age),
as indicated by neurologic examination findings and
Gross Motor Function Classification Scores [32].
Adverse Effects of Iron Supplementation
Several studies included in the systematic review examined
potential adverse effects of iron supplementation, including
oxidative stress, inhibition of nutrient absorption, neonatal
morbidity, the requirement for blood transfusion, and other
adverse effects (Table 5). None of the studies found any evi-
dence that iron supplementation increased oxidative stress
in low birth weight infants [28,30,33]. The study conducted
by Friel et al. was the only study to examine absorption of
other nutrients with iron supplementation and found that
both plasma zinc and copper concentrations were signifi-
cantly higher for the group of infants who received high vs
normal iron supplementation [28]. Three of the 5 studies
that reported on neonatal morbidity found no differences
between the control and treatment groups or dose-
dependent effects of iron supplementation on the overall
incidence of morbidity [31,34,35]. The other 2 studiesTable 4 Effects of iron supplementation on growth and neuro
Study Anthropometric Data
Hall et al. 1993[25] No differences in growth rate, length, head circ




Aggarwal et al. 2005[29] No differences in weight, length, head circumf
Sankar et al. 2009[34] No difference in weight
Berglund et al. 2010[35] No differences in weight, length, head circumf
GDA, Griffiths’ Development Assessment; HTZ, height for age z score; suppl., supplefound that there was a tendency for there to be a higher
prevalence of respiratory tract infection in the iron supple-
mentation group compared with the control group [29] or
the high compared with the normal iron supplementation
group [28]. Two out of 3 studies examining the need for
blood transfusion found no effect of iron supplementation,
[30,34] whereas Arnon et al. reported that significantly
more infants who started iron supplementation at 4 weeks
of age required blood transfusions than infants who started
iron supplementation at 2 weeks of age [31]. Another ad-
verse effect reported by Aggarwal et al. included mild
vomiting (2/32 infants in the treatment group vs 0/30
infants in the control group) [29].
Discussion
This is the first systematic review to focus on the effects of
iron supplementation in low birth weight / premature
infants. Only a relatively small number (N=15) of studies
were identified for review. Several consistent findings were
apparent with iron supplementation, including increased
concentrations of hematologic indicators of iron status,
decreased prevalence of ID / IDA, and a lack of an effect
on growth parameters. Few studies that met the criteria for
inclusion in our review reported on the effects of iron
supplementation on neurodevelopment or the occurrence
of adverse effects.
Our observation that iron supplementation generally
increased concentrations of hematologic indicators of
iron status (notably hemoglobin, hematocrit, and serum
ferritin) in low birth weight / premature infants isdevelopment in low birth weight infants
Neurodevelopmental Outcome
umference NA
e No difference in GDA; no infant had abnormal development
More infants in the late iron suppl. group had abnormal
neurologic examination; no differences in cognitive
development, mobility, hearing, vision, growth; late vs early
iron suppl. was not an risk factor for abnormal neurologic




ment; WTZ, weight for age z score; NA, not available.
Table 5 Adverse effects of iron supplementation in low birth weight infants
Study Oxidative stress Inhibition of Other
Nutrient Absorption
Neonatal Morbidity Blood Transfusion Other Adverse
Effects








Friel et al. 2001[28] No differences in MDA,
SOD, CAT between the
high and normal groups;






infection greater in the
high group
NA NA
Miller et al. 2006[30] No differences in blood
or urine isoprostanes
NA NA No difference NA
Arnon et al. 2007[31] NA NA No difference More transfusions in
the 4 wk group vs
the 2 wk group (10/
36 vs 1/32)
NA






NA NA NA NA
Aggarwal et al. 2005[29] NA NA Prevalence of respiratory
infection or bronchiolitis
slightly higher in T vs C
group (10/32 vs 3/30)
NA 2 infants in the T
group reported
mild vomiting
Sankar et al. 2009[34] NA NA No difference (19 vs 22 %
for T and C groups)
No difference (10 vs
13 for T and C
groups)
NA
Berglund et al. 2010[35] NA NA No difference NA NA
C, control; CAT, catalase; GHSPx, glutathione peroxidase; MDA, malondialdehyde; PLCU, plasma copper; PLZN, plasma zinc; T, iron supplementation group; SOD,
superoxide dismutase; NA, not available.
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meta-analyses which examined the effects of iron supple-
mentation on hematologic indicators of iron status in chil-
dren [16] and young children [17]. Unsurprisingly, given
the improvements in iron status, there were correspond-
ing decreases in the prevalence of ID/IDA among infants
who received iron supplementation. Similar to our review,
the findings of several systematic reviews / meta-analyses
indicate that iron supplementation does not increase
growth in children [18,19]. We must emphasize, however,
that both the studies included in our review and the previ-
ous systematic reviews / meta-analyses typically focused
on assessing growth within the first 12 months of supple-
mentation and did not assess longer term growth after
iron supplementation. The longer term effect of iron sup-
plementation on growth in low birth weight / premature
infants remains to be determined.
As low birth weight / premature infants are particularly
vulnerable, and given the fact that humans have no physio-
logic mechanism for excreting iron, it is important toconsider the possibility of iron overload with iron supple-
mentation and identify any potential adverse effects of iron
supplementation. Adverse effects of iron supplementation
have been suggested, including oxidative stress [36] and an
increased risk infection [17]. None of the studies included
in our review described any evidence of increased oxidative
stress with iron supplementation; however, two studies
reported an increased incidence of respiratory tract infec-
tion with iron supplementation. Given that iron (and other
nutrients) can promote bacterial colonization, an increased
risk of respiratory infection is a plausible potential adverse
effect of iron supplementation. Further evidence is needed
to confirm or deny this possibility. Overall, there were no
consistent adverse effects of iron supplementation; however,
not all studies monitored for adverse effects of iron supple-
mentation and there was considerable between study vari-
ability in the types of adverse effects monitored / reported.
Clearly, further studies are on needed on the potential ad-
verse effects of iron supplementation in low birth weight /
premature infants.
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that must be acknowledged. Perhaps the most important
limitation is was the lack homogeneity between studies
in terms of treatment dose, length of treatment, timing
of treatment, age of the infants, length of follow-up, and
variables assessed. These differences clearly make be-
tween study comparisons difficult and almost certainly
explain some of the variability in findings. Another limi-
tation is that the length of follow-up was relatively short
for the assessment of growth and neurodevelopment. It
is possible that any beneficial effects of iron supplemen-
tation on development may become apparent many
years after supplementation has ceased. Indeed, in the
only study with follow-up> 18 months, Steinmacher
et al. found that more infants who received late vs early
iron supplementation had abnormal neurologic examin-
ation findings at a median of 5.3 years of age [32]. Al-
though a method of randomization was used in most
(10/15) studies included in our systematic review, the
number of infants included in all studies was relatively
small, thus reducing statistical power. Larger scale stud-
ies are clearly needed. With regards to the literature
search process, we acknowledge the limitation of only
considering English language articles for inclusion.
Conclusions
In conclusion, our review leads us to suggest that iron
supplementation can improve indicators of hematologic
iron status and reduce the occurrence of ID / IDA in
low birth weight / premature infants. The benefits of
iron supplementation on growth appear to be limited, at
least in the short term (within 18 months of treatment),
whereas there is insufficient evidence on the effects of
iron supplementation on neurodevelopment or the oc-
currence of adverse events in this population. Quite
clearly larger scale, randomized controlled trials are
needed to determine whether iron supplementation in
low birth weight / premature infants affects neurodeve-
lopment (short and long term) and long term growth,
and to comprehensively monitor potential adverse
effects. Such studies should also aim to determine if spe-
cific cohorts of low birth weight / premature infants are
more likely to benefit from iron supplementation, and
the optimal dose, timing, and duration of iron
supplementation.
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